



Michael A. Cahill, Ph.D.

Lecturer in Biochemistry and Cell Biology
Charles Sturt University
New South Wales, Australia

Michael Cahill, Ph.D. joined Charles Sturt University in 2008 and serves as a lecturer in biochemistry and molecular cell biology at the School of Biomedical Sciences. In 2016, Dr. Cahill was elected to the CSU Academic Senate, the university's highest level of academic decision making and quality assurance.

Prior to his academic appointment in Australia, Dr. Cahill spent 18 years in Germany where in 2000 he co-founded a proteomics-based biotechnology company with the goal of developing and commercializing a platform for improved protein detection. In 2001, the firm underwent a corporate merger to form ProteoSys AG, where he served on the managerial board and as chief research officer. At ProteoSys, Dr. Cahill directed the team that discovered differential PGRMC1 phosphorylation in cancer, a discovery that led to several patent applications. Dr. Cahill returned to his native Australia to pursue the characterization of PGRMC1 in a university environment and has advanced this research during his academic tenure. At CSU, his research interests revolve around the role of the PGRMC1 protein in cell biology and cellular metabolic regulation.

In addition to his research responsibilities, Dr. Cahill is a member of the Australian Society for Biochemistry and Molecular Biology (ASBMS) and a member of the Cognition Therapeutics, Inc. scientific advisory board. He is currently a development grant commercial expert reviewer and a project grant reviewer for the National Health and Medical Research Council (NHMRC), Australia's premier funding body for medical research.